New Treatment Addressing the Pathogenesis of Psoriasis
Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibi...
Main Authors: | Michio Tokuyama, Tomotaka Mabuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/20/7488 |
Similar Items
-
Inhibiting Sphingosine Kinase 2 Derived-sphingosine-1-phosphate Ameliorates Psoriasis-like Skin Disease via Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes in Mice
by: Sun-Hye Shin, et al.
Published: (2019-03-01) -
Experimental Pharmacological Management of Psoriasis
by: Campione E, et al.
Published: (2021-07-01) -
Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases
by: Sara Grassi, et al.
Published: (2019-07-01) -
Sphingosine 1-Phosphate Receptor 4 Expression in Colorectal Cancer Patients
by: Suchittra SAMUHASANEETO, et al.
Published: (2016-06-01) -
A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes
by: Sun-Hye Shin, et al.
Published: (2020-11-01)